116 related articles for article (PubMed ID: 38420826)
21. CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.
Wang G; Fu J; Liu M; Zheng Q
PLoS One; 2024; 19(1):e0277872. PubMed ID: 38232115
[TBL] [Abstract][Full Text] [Related]
22. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
23. SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma.
Zhang B; Zhou Q; Xie Q; Lin X; Miao W; Wei Z; Zheng T; Pang Z; Liu H; Chen X
Aging (Albany NY); 2020 Dec; 13(2):2803-2821. PubMed ID: 33408271
[TBL] [Abstract][Full Text] [Related]
24. RNA modification regulator DDC in endometrial cancer affects the tumor microenvironment and patient prognosis.
Zhao H; Shi C; Zhao G; Liu J; Wang X; Liang J; Li F
Sci Rep; 2023 Oct; 13(1):18057. PubMed ID: 37872211
[TBL] [Abstract][Full Text] [Related]
25. Deciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus endometrial carcinoma.
Wu Q; Tian R; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1139126. PubMed ID: 36936912
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Analysis of ESRRA in Endometrial Cancer.
Wang S; Huo X
Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
[TBL] [Abstract][Full Text] [Related]
27. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
Liu J; Ji C; Wang Y; Zhang C; Zhu H
Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
[TBL] [Abstract][Full Text] [Related]
28. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
Zheng J; Zhang YW; Pan ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
[TBL] [Abstract][Full Text] [Related]
29. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.
Yang J; Li H; Hu S; Zhou Y
Aging (Albany NY); 2020 Apr; 12(8):6518-6535. PubMed ID: 32339157
[TBL] [Abstract][Full Text] [Related]
30. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
31. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
32. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
33. Immune Infiltrates of m5C RNA Methylation-Related LncRNAs in Uterine Corpus Endometrial Carcinoma.
Gu WX; Chen Y; Wang W
J Oncol; 2022; 2022():1531474. PubMed ID: 35392434
[TBL] [Abstract][Full Text] [Related]
34. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
[TBL] [Abstract][Full Text] [Related]
35. SPC25 promotes hepatocellular carcinoma metastasis via activating the FAK/PI3K/AKT signaling pathway through ITGB4.
Shi WK; Shang QL; Zhao YF
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35293598
[TBL] [Abstract][Full Text] [Related]
36. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
37. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
Tian Y; Wen F; Wang S; Lv N
Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
[TBL] [Abstract][Full Text] [Related]
38. CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma.
Xue S; Su XM; Ke LN; Huang YG
Front Oncol; 2023; 13():1077780. PubMed ID: 36845675
[TBL] [Abstract][Full Text] [Related]
39. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
[TBL] [Abstract][Full Text] [Related]
40. A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer.
Lei P; Wang H; Yu L; Xu C; Sun H; Lyu Y; Li L; Zhang DL
Int Immunopharmacol; 2022 Jul; 108():108743. PubMed ID: 35413679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
